Announcements

We have expanded our open access portfolio with eight new journals publishing their inaugural issues in December 2025, as well as three journal transfers. These additions span physical sciences, social sciences, arts and humanities, environmental and Earth sciences, medicine and pharmacology, and public health and healthcare. We extend our sincere thanks to the Editors-in-Chief, Associate Editors, and Editorial Board Members who are shaping these journals’ direction. All journals uphold strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).

MDPI is excited to announce its participation as an exhibitor at the 2026 Society For Biomaterials Annual Meeting & Exposition (SFB 2026), taking place in Atlanta, USA, from 25 to 28 March 2026.

The Society For Biomaterials (SFB)’s Annual Meeting is the preeminent conference for biomaterials science. Each year, the Society provides a diverse program of sessions, panels, and workshops relating to special interest groups, specific topics, and important issues. The meeting is a welcoming community of academics, industry leaders, scientists, and students, networking and discussing the latest research and innovations in the field. The Annual Meeting provides an academic and social environment for connection and knowledge to be obtained by each individual.

The theme for the SFB 2026 Annual Meeting is Biomaterials at the Crossroads: Connecting Science, Industry, and Innovation. This is where the future of biomaterials unfolds!

The following MDPI journals will be presented at the conference:

• Bioengineering;
• Journal of Functional Biomaterials;
• Biomolecules;
• Journal of Pharmaceutical and BioTech Industry;
• Prosthesis;
• Materials;
• Future Pharmacology;
• Pharmaceutics;
• Biomedicines.

If you are attending this conference, please feel free to contact us. Our delegates look forward to meeting you in person at booth #401 and answering any questions that you may have. For more information about the conference, please visit the following link: https://meetings.biomaterials.org/.

We are pleased to announce updates to our article template, aimed at improving the readability and visual appeal of our publications. The following updates will be applied to articles published in volumes in 2026, starting from 19 December 2025.

Left information bar:

• Updated the logo and URL for “Check for updates”;
• Removed the “Citation” section (Note: Citation details remain accessible via “Cite” in the online article version);
• Changed the link in “Copyright” to a hyperlink format.

Footer:

• Added a DOI link at the bottom-right corner of each page.

The updated template is now available for download from the Instructions for Authors page of each journal.

We hope that the new version of the template will provide users with better experience and make the process more convenient.

For any questions or suggestions, please contact our production team at production@mdpi.com.

Editor’s Choice Articles are selected based on suggestions from the academic editors of Pharmaceutics (ISSN: 1999-4923). The editors select a small number of published articles that they consider particularly interesting to our readers or important in their respective fields of research. You are therefore invited to read the Editor’s Choice Articles, a curated list of high-quality articles published in Pharmaceutics in March 2025. The full list of Editor’s Choice Articles can be viewed via the following link: https://www.mdpi.com/journal/pharmaceutics/editors_choice.

1. “Development of Inhalable Bacteriophage Liposomes Against Pseudomonas aeruginosa”
by Shruti S. Sawant, Maizbha Uddin Ahmed, Nathan-Gautham Gantala and Caitlin Chiu
Pharmaceutics 2025, 17(4), 405; https://doi.org/10.3390/pharmaceutics17040405
Editor’s highlight: The article investigates alternative therapeutic strategies to conventional antibiotics for combating major respiratory pathogens such as Pseudomonas aeruginosa. In this study, the authors developed liposome-encapsulated bacteriophage formulations intended for pulmonary delivery via nebulization.
The findings are particularly compelling. Formulations exhibiting favorable encapsulation efficiency (58 ± 6.02%) achieved a sustained and controlled release of phages over a 10-hour period. Furthermore, liposomal encapsulation markedly mitigated phage viability loss during nebulization, decreasing from 1.55 ± 0.04 log in phage suspensions to 1.08 ± 0.05 log in liposome-encapsulated preparations.
The authors concluded that liposomal encapsulation not only resulted in a twofold reduction in phage cellular uptake but also prolonged extracellular phage retention within human lung epithelial cell monolayers. Collectively, these results demonstrate that liposomal encapsulation enhances phage stability and bioavailability, thereby improving their potential for antibacterial efficacy.

2. “Simvastatin-Loaded Chitosan-Functionalized PLGA Nanoparticles: Characterization and Use in Intimal Hyperplasia Therapy”
by Ashley A. Peters, Chanpreet Kaur, Maleen Cabe, Kelly A. Langert, Kristopher Maier and Vivian Gahtan 
Pharmaceutics 2025, 17(3), 391; https://doi.org/10.3390/pharmaceutics17030391
Editor’s highlight: In this article chitosan-functionalized PLGA nanoparticles loaded with simvastatin (SL-cNPs) were developed to treat intimal hyperplasia after vascular interventions. When combined with oral simvastatin, local SL-cNPs delivery significantly reduced intimal hyperplasia in rats by targeting endothelial and smooth muscle cells and modulating key vascular genes.
This dual approach minimizes systemic side effects and enhances vascular repair, but optimal benefit required both local and systemic therapy. The strategy points to a promising direction for improving outcomes and reducing restenosis in peripheral arterial disease.

3. “Pharmaceutical 3D Printing Technology Integrating Nanomaterials and Nanodevices for Precision Neurological Therapies”
by Jurga Bernatoniene, Mindaugas Plieskis and Kestutis Petrikonis
Pharmaceutics 2025, 17(3), 352; https://doi.org/10.3390/pharmaceutics17030352
Editor’s highlight: This is a review article that discusses the current state, applications, and transformative potential of 3D printing and nanotechnology in neurological treatment. 3D printing technology now integrates nanomaterials and nanodevices to deliver drugs precisely to the central nervous system, enabling personalized treatment of neurological diseases. This breakthrough allows multi-ingredient combinations in single tablets with programmable release kinetics, improving CNS drug delivery across the blood-brain barrier.
Key advantages include better patient compliance through reduced dosing, customizable formulations, and lower systemic toxicity. While production costs and regulatory pathways remain challenges, advances in materials science promise rapid clinical translation, particularly benefiting patients with swallowing difficulties and those requiring narrow therapeutic windows.

4. “The Role of Natural Deep Eutectic Solvents in a Hydrogel Formulation Containing Lidocaine”
by Feria Hasanpour, Mária Budai-Szűcs, Anita Kovács, Anita Kovács, Orsolya Jójárt-Laczkovich, Boglárka Szalai, Branimir Pavlić, Péter Simon, Levente Törteli and Szilvia Berkó
Pharmaceutics 2025, 17(3), 324; https://doi.org/10.3390/pharmaceutics17030324
Editor’s highlight: In this article researchers developed a Natural Deep Eutectic Solvents (NADESs) hydrogel containing lidocaine using green chemistry principles—choline chloride and citric acid—delivering 50% faster drug release and superior skin permeation compared to conventional ointments. The formulation achieves complete dissolution in 5 minutes with validated chemical stability and minimal skin irritation.
This sustainable, biodegradable approach offers potentially faster anesthesia onset (15-30 minutes) than EMLA cream while maintaining excellent skin barrier protection. With natural, inexpensive raw materials and scalable manufacturing, NADESs-hydrogel represents a cost-effective alternative for topical anesthesia, chronic pain management, and pediatric procedures.

5. “Analysis of Polymer/siRNA Nanoparticle Efficacy and Biocompatibility in 3D Air–Liquid Interface Culture Compared to 2D Cell Culture”
by Sandra Noske, Martin Krueger, Alexander Ewe and Achim Aigner
Pharmaceutics 2025, 17(3), 339; https://doi.org/10.3390/pharmaceutics17030339
Editor’s highlight: The study bridges polymer chemistry, nanomedicine, and advanced in vitro modeling, offering practical guidance for developing safe and effective siRNA nanocarriers. Its novelty, rigor, and translational potential make it a strong candidate for Editor’s Choice recognition.
This article exemplifies the Pharmaceutics mission to promote innovative and translational research in pharmaceutical sciences. It stands out through:

• Innovation – Introduction of a novel fluoroalkyl-modified PEI polymer for siRNA delivery;
• Methodological Strength – A direct, systematic comparison of 2D vs. 3D ALI culture systems, addressing a critical challenge in nanocarrier evaluation;
• Relevance – Direct applicability to pulmonary RNA therapeutics, an area of growing importance;
• Scientific Contribution – Identification of polymer structure–activity relationships and demonstration of ALI models as predictive tools for nanoparticle efficacy and biocompatibility;
• Quality and Clarity – Excellent scientific communication and data integrity.

6. “Nasal Administration of a Nanoemulsion Based on Methyl Ferulate and Eugenol Encapsulated in Chitosan Oleate: Uptake Studies in the Central Nervous System”
by Giada Botti, Giada Botti, Alessandro Dalpiaz, Luca Randi, Maria Cristina Bonferoni, Sara Perteghella, Sarah Beggiato, Luca Ferraro, Barbara Pavan and Milena Sorrenti
Pharmaceutics 2025, 17(3), 367; https://doi.org/10.3390/pharmaceutics17030367
Editor’s highlight: The manuscript is well-structured and presents a strong scientific rationale. The proposed nanoemulsions are thoroughly characterized from a physicochemical perspective and subsequently evaluated both in vitro and in vivo. The study is comprehensive, demonstrating a well-conceived research design, rigorous experimental execution, and robust characterization and application results. Overall, this work represents an excellent example of high-quality pharmaceutical research and fully merits consideration for the Editor’s Choice designation.

7. “Nanotechnology-Based Therapies for Preventing Post-Surgical Adhesions”
by Zi Yi Teo, Samyuktha Dhanalakshmi Senthilkumar and Dinesh Kumar Srinivasan
Pharmaceutics 2025, 17(3), 389; https://doi.org/10.3390/pharmaceutics17030389
Editor’s highlight: This review addresses the challenge of postoperative adhesions—common complications arising from surgery that can lead to serious outcomes such as pain and intestinal obstruction. While several prevention strategies currently exist, many are associated with side effects. In contrast, nanotherapeutics present a promising alternative, although they remain in the early stages of development. This article examines current nanotherapeutic approaches for adhesion prevention and explores their regulatory, safety, and ethical considerations, offering a comprehensive overview of the field's current progress.

8. “Targeting Neuroinflammation in Central Nervous System Diseases by Oral Delivery of Lipid Nanoparticles”
by Yuan Zou, Jing Zhang, Longmin Chen, Qianqian Xu, Sheng Yao and Hong Chen
Pharmaceutics 2025, 17(3), 388; https://doi.org/10.3390/pharmaceutics17030388
Editor’s highlight: This review provides a thorough and timely overview of recent progress on oral lipid nanoparticles as emerging carriers for modulating neuroinflammation in central nervous system disorders. By clearly outlining the challenges posed by the blood–brain barrier and highlighting how orally administered LNPs can enhance bioavailability, improve targeting, and support therapeutic efficacy, the authors offer valuable insight into a rapidly evolving field. The article’s balanced discussion of mechanisms, formulation strategies, and clinical relevance makes it an impactful and well-structured contribution, well suited for Editor’s Choice recognition.

Conference: The 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka)
Date: 26–29 March 2026
Location: Osaka, Japan

MDPI will be attending the 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka) as an exhibitor, which will be held from 26 to 29 March 2026, and we welcome researchers from diverse backgrounds to visit and share their latest ideas with us.

Pharmaceutical sciences are comprehensive sciences that require expertise from a wide range of academic fields, including physics, chemistry, biology, medical sciences, and clinical sciences. In order to overcome the various challenges surrounding pharmaceutical sciences today, cross-disciplinary collaboration beyond traditional boundaries has become increasingly important and will be emphasized and discussed during the 146th Annual Meeting of the Pharmaceutical Society of Japan (Osaka).

The conference is organized by the Pharmaceutical Society of Japan and chaired by Prof. Takashi Ohshima from the Graduate School of Pharmaceutical Sciences, Kyushu University. The theme is Promoting the Ecosystem in Pharmaceutical Sciences: Future Innovation through Cross-disciplinary Collaboration. This conference will bring together around 5,000 scientists and students to share research advances covering a wide range of scientific topics. The sessions include, but are not limited to, the following: (1) Pharmaceutical Chemistry; (2) Pharmaceutical Physics; (3) Pharmaceutical Biology; (4) Pharmaceutical Health Science and Environmental Toxicology; (5) Pharmaceutical Health Care and Sciences; and (6) Others.

The following MDPI journals will be represented at the conference:

• Pharmaceuticals;
• Diseases;
• Pharmacy;
• Applied Biosciences;
• Antibodies;
• Biomedicines;
• Future Pharmacology;
• JPBI;
• JPM;
• Marine Drugs;
• Medicines;
• Pharmaceutics;
• Pharmacoepidemiology.

On 17 December 2025, MDPI and Pharmaceutics (ISSN: 1999-4923) will host a webinar titled “Extemporaneous Formulations: Filling the Gap in the Pharmaceutical Industry with Personalized Medicines”.

This event will bring together distinguished experts and practitioners to discuss the evolving role of customised medications within modern healthcare.

Extemporaneous formulations embody the true essence of personalised medicine—allowing for tailored treatments that respond to specific patient needs when industrially manufactured products are unavailable or unsuitable. Recent advances in compounding technologies, materials, and regulatory approaches have strengthened the scientific foundation of these preparations, ensuring higher standards of quality, safety, and reproducibility.

At the same time, this field continues to face challenges—from standardisation and scalability to ensuring consistent therapeutic outcomes. Through this webinar, we aim to explore how innovation, collaboration, and patient-centred thinking can transform these challenges into opportunities for growth and global health improvement.

Date: 17 December 2025
Time: 4:00 p.m. CET | 10:00 a.m. EST
Webinar ID: 851 6540 3655

Register now for free!

Program:

After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic or institutional email addresses will be prioritised.

If you are unable to attend, feel free to register nonetheless; we will inform you once a recording of the webinar becomes available.

Webinar Chair and Keynote Speakers:

• Prof. Dr. Nunzio Denora, Department of Pharmacy, Pharmaceutical Sciences, University of Bari Aldo Moro, Italy;
• Prof. Dr. Milap Nahata, Pediatrics and Internal Medicine at the College of Medicine, Ohio State University, USA;
• Dr. Karolina Dziemidowicz, School of Pharmacy, University College London, United Kingdom;
• Dr. Antonio Lopalco, Department of Pharmacy, Pharmaceutical Sciences, University of Bari Aldo Moro, Italy.

Relevant Special Issue:
“Extemporaneous Formulations: Filling the Gap in the Pharmaceutical Industry with Personalized Medicines, 2nd Edition”
Guest Editors: Dr. Antonio Lopalco and Prof. Dr. Nunzio Denora
Deadline for Manuscript Submission: 31 May 2026

For more information about this webinar, please visit the following link: https://sciforum.net/event/Pharmaceutics-5.

If you have any questions about this webinar, please contact:  journal.webinar@mdpi.com.

Pharmaceutics Webinar Secretariat

We are pleased to announce that the 2^nd International Conference on Bioengineering (BIOENG 2026) is back and it will take place from 11 to 13 November 2026 in Barcelona, Spain.

This conference is organized by MDPI’s open access journal Bioengineering (ISSN: 2306-5354, Impact Factor 3.7). Following the success of IOCBE 2024, an earlier edition in this series, BIOENG 2026 aims to gather leading minds from around the world once more to discuss transformative advances in bioengineering at the intersection with AI.

Conference Chairman:

• Prof. Dr. Anthony Guiseppi-Elie, Texas A&M University, USA.

Session topics of interest:
S1. Regenerative engineering;
S2. Biochemical engineering;
S3. Biosignal processing;
S4. Biomedical engineering and biomaterials;
S5. Biomechanics and sports medicine;
S6. Cellular and Molecular Bioengineering.

Important dates:
Deadline for abstract submission: 7 July 2026;
Abstract notification of acceptance: 6 September 2026;
Deadline for Early Bird registration: 7 September 2026;
Deadline for covering author registration: 17 September 2026;
Deadline for registration: 4 November 2026.

Guide for authors:

To submit your abstract, please click on the following link: https://sciforum.net/user/submission/create/1424.

To register for the event, please visit the following website: https://sciforum.net/event/BIOENG2026?section=#registration.

For details regarding abstract submission, poster and slide submission, and publication opportunities, please refer to the “Instructions for Authors” section: https://sciforum.net/event/BIOENG2026?section=#instructions.

We welcome you to partake in this opportunity to contribute to and shape the AI-enabled evolution of bioengineering.

For any enquiries regarding this event, please contact bioeng2026@mdpi.com.

1 December is World AIDS Day, the day is an opportunity for public and private partners to spread awareness about the status of the pandemic and encourage progress in HIV/AIDS prevention, treatment, and care around the world. It has become one of the most widely recognized international health days.

In recognition of this day, we recommend the following related articles, Special Issues, and journals spanning multidisciplinary fields, including clinical medicine and biology. We believe that sharing such research can raise the public’s awareness and understanding of AIDS. The aim is to strengthen scientific cooperation in response to increased awareness about HIV/AIDS and to demonstrate international solidarity in the face of the pandemic.

“Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview”
by Alex C. Boomgarden and Chitra Upadhyay
Vaccines 2025, 13(2), 148; https://doi.org/10.3390/vaccines13020148

“Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know”
by Emanuela De Bellis, Danilo Donnarumma, Adele Zarrella, Salvatore Maria Mazzeo, Annarita Pagano, Valentina Manzo, Ines Mazza, Francesco Sabbatino, Graziamaria Corbi, Pasquale Pagliano et al.
Pharmaceutics 2025, 17(1), 31; https://doi.org/10.3390/pharmaceutics17010031

“High Prevalence of High-Risk HPV Among People with and Without HIV: Insights into Risk Factors for Tailored Screening Approaches”
by Elena Bruzzesi, Federica Gandini, Sara Diotallevi, Riccardo Lolatto, Massimo Cernuschi, Caterina Candela, Angelo Roberto Raccagni, Flavia Passini, Andrea Marco Tamburini, Roberto Burioni et al.
Microorganisms 2024, 12(12), 2571; https://doi.org/10.3390/microorganisms12122571

“Association Between Left Ventricular Diastolic Dysfunction, Systemic Inflammation, and Gastrointestinal Symptoms in HIV-Positive Patients on Antiretroviral Therapy”
by Madalina-Ianca Suba, Bogdan Hogea, Ahmed Abu-Awwad, Voichita Elena Lazureanu, Ovidiu Rosca, Daniela Gurgus, Sorina Maria Denisa Laitin and Alina Abu-Awwad
Diseases 2024, 12(12), 313; https://doi.org/10.3390/diseases12120313

“NSC95397 Is a Novel HIV-1 Latency-Reversing Agent”
by Randilea Nichols Doyle, Vivian Yang, Yetunde I. Kayode, Robert Damoiseaux, Harry E. Taylor and Oliver I. Fregoso
Viruses 2024, 16(11), 1783; https://doi.org/10.3390/v16111783

“HIV Self-Testing: A Discussion on the Benefits, Limitations, and Implications for Public Health with a Focus on Poland”
by Aleksandra Kozieł, Igor Domański, Aleksandra Szymczak, Tomasz Dudzik, Brygida Knysz and Bartosz Szetela
Diagnostics 2024, 14(22), 2475; https://doi.org/10.3390/diagnostics14222475

“Tumor Initiation and Progression in People Living on Antiretroviral Therapies”
by Seun E. Olufemi, Daniel A. Adediran, Temitope Sobodu, Isaac O. Adejumo, Olumide F. Ajani and Elijah K. Oladipo
Biologics 2024, 4(4), 390-406; https://doi.org/10.3390/biologics4040024

“J3ExoA: A Novel Anti-HIV Immunotoxin Fusion of Anti-Gp120 J3VHH and PE38 Fragment of Pseudomonas Exotoxin A”
by Seth H. Pincus, Kun Luo, Tami Peters, James T. Gordy, Frances M. Cole, Grant Klug, Kelli Ober, Tamera K. Marcotte and Richard B. Markham
Pharmaceuticals 2025, 18(9), 1305; https://doi.org/10.3390/ph18091305

“A Memo on Factors Associated with Perception of Stigma Attached to PrEP: Evidence from the Keeping It LITE Study”
by Shahin Davoudpour, Gregory L. Phillips II, Pedro A. Serrano, Audrey L. French and Sybil G. Hosek
Sexes 2024, 5(3), 300-316; https://doi.org/10.3390/sexes5030023

“Effects of E-Cigarettes on the Lung and Systemic Metabolome in People with HIV”
by Aline Zaparte, Courtney J. Christopher, Connie Arnold, Lauren Richey, Adairre Castille, Kyle Mistretta, Christopher M. Taylor, Huiyi Lin, Steve Nelson, John P. Kirwan, John W. Apolzan, Shawn R. Campagna and David A. Welsh
Metabolites 2024, 14(8), 434; https://doi.org/10.3390/metabo14080434

“Bone Tissue Changes in Individuals Living with HIV/AIDS: The Importance of a Hierarchical Approach in Investigating Bone Fragility”
by Jelena Jadzic, Gordana Dragovic, Relja Lukic, Bozana Obradovic and Marija Djuric
J. Pers. Med. 2024, 14(8), 791; https://doi.org/10.3390/jpm14080791

“Advanced Therapies for Human Immunodeficiency Virus”
by Daniel Josef Lindegger
Med. Sci. 2024, 12(3), 33; https://doi.org/10.3390/medsci12030033

“Antiretroviral Therapy Switch in HIV-Infected Adults from a Regional HIV/AIDS Center in NE Romania”
by Isabela Ioana Loghin, Șerban Alin Rusu, Andrei Vâţă, Mihaela Cobaschi, Ion Cecan, Carmen Manciuc and Carmen Mihaela Dorobăţ
Medicina 2024, 60(6), 854; https://doi.org/10.3390/medicina60060854

“Alterations in the Gut Microbiome Composition of People Living with HIV in the Asia–Pacific Region: A Systematic Review”
by Paul Benedic U. Salvador, Patrick Josemaria d. R. Altavas, Mark Angelo S. del Rosario, Eric David B. Ornos and Leslie Michelle M. Dalmacio
Clin. Pract. 2024, 14(3), 846-861; https://doi.org/10.3390/clinpract14030066

“Systematic Review: HIV, Aging, and Housing—A North American Perspective, 2012–2023”
by Arthur S. Chaminuka, Gayle Prybutok, Victor R. Prybutok and William D. Senn
Healthcare 2024, 12(10), 992; https://doi.org/10.3390/healthcare12100992

“The Role of MicroRNAs in HIV Infection”
by Nicolas Morando, Mara Cecilia Rosenzvit, Maria A. Pando and Jens Allmer
Genes 2024, 15(5), 574; https://doi.org/10.3390/genes15050574

“HIV-TB Co-Infection and Pediatric Pathogen Dynamics” Guest Editor: Dr. Boris Kevin Tchounga Submission deadline: 15 March 2026	“HIV Expression in Diverse Cell Types: Mechanisms, Regulation, and Pathogenesis” Guest Editor: Dr. Rosemary Kiernan Submission deadline: 20 March 2026
“Research on HIV/AIDS Vaccine” Guest Editors: Dr. Portia Chipo Mutevedzi and Dr. Nagesh Kolishetti Submission deadline: 31 May 2026	“Gene and Cell Therapy: New Findings from Medical Research and Treatment” Guest Editors: Dr. Lorella Tripodi and Dr. Antonio Di Stasi Submission deadline: 30 June 2026
“Emerging Knowledge on Human Immunodeficiency Virus” Guest Editors: Dr. Giota Lourida and Prof. Dr. Dimitrios Paraskevis Submission deadline: 22 July 2026	“Nutrition Intervention in HIV Patients” Guest Editors: Dr. Meena Mahadevan Submission deadline: 10 August 2026

World Diabetes Day will take place on 14 November 2025, under the theme “Diabetes and well-being”. Diabetes is a major cause of blindness, kidney failure, heart attack, stroke and lower limb amputation. A healthy diet, physical activity and avoiding tobacco use can prevent or delay type 2 diabetes. In addition, diabetes can be treated and its consequences avoided or delayed with medication, regular screening and treatment for complications.

In recognition of this important day, we recommend the following related articles, Special Issues and journals spanning multidisciplinary fields, including clinical medicine, biology and material sciences. We believe th.at promoting such research contributes to enhanced public awareness of innovative ideas regarding the prevention, treatment and care of diabetes. This World Diabetes Day, 14 November, let us put well-being at the heart of diabetes care and start the change for a better life with diabetes.

“New-Onset Diabetes After Transplantation in Renal Recipients: A Pilot Comparative Study of Immediate vs. Extended-Release Tacrolimus Formulation”
by Ioana Adela Ratiu, Florin Bănică, Corina Moisa, Bianca Pașca, Daniela Gîtea, Iulia Dana Grosu, Gabriel Cristian Bako, Oliviu Voștinaru, Wael Abu Dayyih and Lorena Filip
Pharmaceuticals 2025, 18(10), 1532; https://doi.org/10.3390/ph18101532

“From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments”
by Francesc Cabré, Josep J. Centelles and Marta Cascante
Pharmaceutics 2025, 17(9), 1125; https://doi.org/10.3390/pharmaceutics17091125

“Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy”
by Laila Schneidewind, Bernhard Kiss, Friedemann Zengerling, Annemarie Uhlig, Niklas Klümper, Thomas Büttner, Julia Heinzelbecker, Thomas Elegeert, Cem Aksoy, Cindy Rönnau et al.
Biologics 2025, 5(3), 20; https://doi.org/10.3390/biologics5030020

“Gene–Diet Interactions in Diabetes Mellitus: Current Insights and the Potential of Personalized Nutrition”
by Angeliki Kapellou, Effie Salata, Dimitrios Miltiadis Vrachnos, Sevastiani Papailia and Spiros Vittas
Genes 2025, 16(5), 578; https://doi.org/10.3390/genes16050578

“Anti-Diabetic Therapies and Cancer: From Bench to Bedside”
by Dimitris Kounatidis, Natalia G. Vallianou, Irene Karampela, Eleni Rebelos, Marina Kouveletsou, Vasileios Dalopoulos, Petros Koufopoulos, Evanthia Diakoumopoulou, Nikolaos Tentolouris and Maria Dalamaga
Biomolecules 2024, 14(11), 1479; https://doi.org/10.3390/biom14111479

“Untargeted and Targeted Lipidomics Unveil Dynamic Lipid Metabolism Alterations in Type 2 Diabetes”
by Li Feng, Bingshu He, Jianzhen Xia and Zhonghua Wang
Metabolites 2024, 14(11), 610; https://doi.org/10.3390/metabo14110610

“Quality of Dietetic Patient Education Materials for Diabetes and Gastrointestinal Disorders: Where Can We Do Better?”
by Kelly Lambert, Olivia Hodgson and Claudia Goodman
Dietetics 2024, 3(3), 346-356; https://doi.org/10.3390/dietetics3030026

“Biomaterials Designed to Modulate Reactive Oxygen Species for Enhanced Bone Regeneration in Diabetic Conditions”
by Mingshan Li, Zhihe Zhao and Jianru Yi
J. Funct. Biomater. 2024, 15(8), 220; https://doi.org/10.3390/jfb15080220

“The Interrelationship between Diabetes Mellitus and Emotional Well-Being: Current Concepts and Future Prospects”
by Polyxeni Mangoulia, Charalampos Milionis, Eugenia Vlachou and Ioannis Ilias
Healthcare 2024, 12(14), 1457; https://doi.org/10.3390/healthcare12141457

“Are Hyperglycemia-Induced Changes in the Retina Associated with Diabetes-Correlated Changes in the Brain? A Review from Zebrafish and Rodent Type 2 Diabetes Models”
by Kaylee Augustine-Wofford, Victoria P. Connaughton and Elizabeth McCarthy
Biology 2024, 13(7), 477; https://doi.org/10.3390/biology13070477

“Interleukin-6 as a Director of Immunological Events and Tissue Regenerative Capacity in Hemodialyzed Diabetes Patients”
by Maria-Florina Trandafir, Octavian Savu, Daniela Pasarica, Coralia Bleotu and Mihaela Gheorghiu
Med. Sci. 2024, 12(2), 31; https://doi.org/10.3390/medsci12020031

“Euonymus alatus Extract Reduces Insulin Resistance in db/db Mice by Regulating the PI3K–AKT Pathway”
by Seoung-Uk. Lee, Pallavi Gurung, Til Bahadur Thapa Magar, Junmo Lim, Rajeev Shrestha, Yoon-Hee Kim and Yong-Wan Kim
Int. J. Transl. Med. 2024, 4(2), 286-297; https://doi.org/10.3390/ijtm4020018

“Personalized Diabetes Management with Digital Twins: A Patient-Centric Knowledge Graph Approach”
by Fatemeh Sarani Rad, Rasha Hendawi, Xinyi Yang and Juan Li
J. Pers. Med. 2024, 14(4), 359; https://doi.org/10.3390/jpm14040359

“NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay”
by Simona Cernea
Life 2024, 14(2), 272; https://doi.org/10.3390/life14020272

“Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight”
by Franklyn Nonso Iheagwam, Amarachi Joy Joseph, Eniola Deborah Adedoyin, Olawumi Toyin Iheagwam and Samuel Akpoyowvare Ejoh
Pathophysiology 2025, 32(1), 9; https://doi.org/10.3390/pathophysiology32010009

“Is Tirzepatide the New Game Changer in Type 2 Diabetes?”
by Giuseppe Lisco, Olga Eugenia Disoteo, Vincenzo De Geronimo, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Emilio Jirillo and Vincenzo Triggiani
Endocrines 2024, 5(1), 72-86; https://doi.org/10.3390/endocrines5010005

“Fostering Resilience and Wellness: The Synergy of Mindful Eating and the Mediterranean Lifestyle”
by Efstratios Christodoulou, Georgia-Eirini Deligiannidou, Christos Kontogiorgis, Constantinos Giaginis and Antonios E. Koutelidakis
Appl. Biosci. 2024, 3(1), 59-70; https://doi.org/10.3390/applbiosci3010004

“The Main Risk Factors in Type 2 Diabetes for Cognitive Dysfunction, Depression, and Psychosocial Problems: A Systematic Review”
by Maarja Randväli, Toomas Toomsoo and Jekaterina Šteinmiller
Diabetology 2024, 5(1), 40-59; https://doi.org/10.3390/diabetology5010004

“Chronic Kidney Disease in the Older Adult Patient with Diabetes”
by Raja Ravender, Maria-Eleni Roumelioti, Darren W. Schmidt, Mark L. Unruh and Christos Argyropoulos
J. Clin. Med. 2024, 13(2), 348; https://doi.org/10.3390/jcm13020348